| Pathogen-targeted treatment | Empirical treatment | p value |
---|---|---|---|
n = 172 | n = 498 |  | |
Patient background | Â | Â | Â |
Age, median (IQR), y | 80 (72–88) | 76 (63–85) | 0.064 |
Male, n (%) | 90 (52.3) | 340 (68.3) | <0.001 |
Comorbid conditions, n (%) | 163 (94.8) | 472 (94.8) | 0.157 |
CAP, n (%) | 100 (58.1) | 228 (45.8) | 0.005 |
Previous antibiotics treatment, n (%) | 14 (8.1) | 83 (16.7) | 0.006 |
Immunosuppressed, n (%) | 8 (4.7) | 32 (6.4) | 0.40 |
Suspected aspiration, n (%) | 43 (25.0) | 203 (40.8) | <0.001 |
Severity scores | Â | Â | Â |
PSI score, median (IQR) | 108 (89–128) | 112 (90–142) | 0.012 |
PSI class, median (IQR) | 4 (3–4) | 4 (4–5) | 0.002 |
Clinical outcomes | Â | Â | Â |
Initial treatment failure, n (%) | 13 (7.6) | 61 (12.2) | 0.091 |
Antibiotics adverse events, n (%) | 5 (2.9) | 35 (7.0) | 0.049 |
ICU admission, n (%) | 12 (7.0) | 69 (13.9) | 0.017 |
Length of intravenous treatment, median(IQR) | 8 (6–9) | 9 (7–13) | <0.001 |
Length of hospital stay, median (IQR) | 9 (7–13) | 11 (8–21) | <0.001 |
In-hospital mortality, n (%) | 14 (8.1) | 45 (9.0) | 0.72 |